CAR T-cell outcomes
| CAR T-cell outcomes . | Patients N = 280 . |
|---|---|
| Follow up time, median days (range) | 218 (7-1340) |
| Disease progression, n (%) | 122 (44) |
| Days to progression, median (range) | 83 (7-742) |
| Death, n (%) | 68 (24) |
| Days to death, median (range) | 150 (7-664) |
| ANC <1000 after d 30 | 116 (41) |
| IgG <400 after d 30 | 99 (35) |
| IVIG administration after d 30 | 111 (40) |
| CD4 T-cell count <200 after d 30 | 55 (20) |
| CAR T-cell outcomes . | Patients N = 280 . |
|---|---|
| Follow up time, median days (range) | 218 (7-1340) |
| Disease progression, n (%) | 122 (44) |
| Days to progression, median (range) | 83 (7-742) |
| Death, n (%) | 68 (24) |
| Days to death, median (range) | 150 (7-664) |
| ANC <1000 after d 30 | 116 (41) |
| IgG <400 after d 30 | 99 (35) |
| IVIG administration after d 30 | 111 (40) |
| CD4 T-cell count <200 after d 30 | 55 (20) |
IVIG, IV immunoglobulin G.